Related Experiment Videos
[Clinical evaluation of a new parenteral penicillin, aspoxicillin, in children]
Insights
Aspoxicillin (ASPC) demonstrated high efficacy and safety in treating acute bacterial infections in 30 pediatric patients. This antibiotic proved effective in 96.7% of cases, with no adverse reactions reported.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology and Therapeutics
- Clinical Microbiology
Context:
- Acute bacterial infections pose a significant health risk in infants and children.
- Limited treatment options may exist for specific resistant bacterial strains.
- Evaluating novel antibiotics is crucial for pediatric infectious disease management.
Purpose:
- To assess the efficacy and safety of Aspoxicillin (ASPC) in pediatric patients with acute bacterial infections.
- To determine the pharmacokinetic profile of ASPC, including serum half-life and urinary excretion.
- To identify the spectrum of bacterial infections treatable with ASPC.
Summary:
- Aspoxicillin (ASPC) was administered to 30 pediatric patients diagnosed with acute bacterial infections, including respiratory tract, soft tissue, urinary tract infections, sepsis, and meningitis.
- ASPC achieved a high effective rate of 96.7%, with the sole failure attributed to a beta-lactamase-positive H. influenzae pneumonia.
- No adverse reactions or laboratory abnormalities were linked to ASPC therapy, and its serum half-life was approximately 0.88 hours with rapid urinary excretion.
Impact:
- Aspoxicillin (ASPC) is confirmed as a safe and effective antibiotic for treating susceptible bacterial infections in pediatric populations.
- The study provides valuable data supporting the clinical utility of ASPC in pediatric infectious disease treatment.
- Findings contribute to the evidence base for antibiotic selection in children.
Abstract:
Aspoxicillin (ASPC) was evaluated for its efficacy and safety in 30 infants and children with acute bacterial infections. The disease categories included acute respiratory tract (22), soft tissue (3), urinary tract (3) infections, sepsis with pyothorax (1) and purulent meningitis (1). ASPC was effective in all but 1 case of pneumonia due to beta-lactamase-positive H. influenzae (effective rate; 96.7%). Adverse reactions and abnormalities of the laboratory tests were not associated with the ASPC therapy in any of the cases. The serum half-life of ASPC after an intravenous bolus injection was 0.883 +/- 0.194 hour and excretion into urine was rapid. From the present results, ASPC is a safe and effective antibiotic when used in patients with susceptible bacterial infections.